Autonomix is dedicated to transforming patient outcomes with its proprietary precision guidance technology to sense, treat and verify. Through a minimally invasive procedure and utilizing its novel nerve sensing technology, Autonomix is able to identify and target specific nerves throughout the body. Then, through its radio frequency (RF) ablation technology, it can kill responsible nerves and verify signaling has stopped. This approach has the potential to revolutionize therapeutic electrophysiology and can be applied across a number of diseases from chronic pain management to hypertension and cardiology.
The Autonomix Mission
Autonomix’s mission is to dramatically improve the quality of millions of lives by empowering the nerve-targeted treatments of tomorrow. The Company is committed to equipping physicians with innovative tools that allow for unparalleled precision in diagnosis and treatment. This means patients can look forward to more targeted treatments and a renewed sense of hope. With the Company’s groundbreaking technology, Autonomix believes they can enable new procedures that have never before been possible.
Our Precision Approach to Pain Management
Autonomix Medical, Inc. is a medical device company focused on advancing precision nerve-targeted treatments to revolutionize how diseases involving the peripheral nervous system are treated. The Company’s first-in-class platform system technology utilizes a catheter-based microchip sensing array antenna that has the ability to detect and differentiate neural signals with up to 3,000* times greater sensitivity than currently available technologies. Once target nerves are identified, Autonomix uses its proprietary radio frequency (RF) ablation technology to kill targeted nerves, enabling a precision guided sense, treat and verify approach to addressing a number of disease categories from chronic pain management to hypertension and cardiology.
Autonomix is initially developing its precision nerve-targeted technology for the treatment of pain associated with pancreatic cancer. Initial results from the Company’s ongoing first-in-human study have shown clinically meaningful and durable pain reduction in the first 15 responding patients. Demonstrating success in pancreatic cancer pain provides the opportunity for Autonomix to quickly move into additional cancer pain and abdominal pain indications exponentially expanding the full market opportunity.
* Data on File